Solana validators are urged to upgrade to Agave version 4.4.1 by Nov 6, 2026, to avoid being excluded from the network at epoch 1079. This upgrade includes a critical fix for loader-v3 ProgramData accounts, essential for compatibility with upcoming protocol changes. Validators not updating risk losing consensus participation and rewards. Alternatively, the Firedancer client version 26.10.6 also meets the new requirements. The upgrade deadline is tight, with the epoch transition expected around 13:30 UTC on Nov 6, making immediate action necessary for validator operators.
Solana validators upgrading to Agave 4.4.1 face a tight deadline with epoch 1079 approaching. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 06, 2026 03:03 WIB: out of 50 major cryptocurrencies, 5 rose and 44 fell today. Notable movers include SNX at Rp3.029 with a -7.48% change and balanced buy/sell activity, THETA at Rp2.627 down 7.37%, and FIL at Rp14.594 down 6.81% with strong buy interest.
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Following Binance's $6.3 billion hack, the Federal Reserve and the Office of the Comptroller of the Currency (OCC) have contacted U.S. banks to inquire about any unusual activity, service disruptions, or system vulnerabilities. This oversight aims to...
Windward Bio Group AG plans to raise over $100 million through a U.S. IPO to support the development of its clinical-stage asthma drug, WIN378, which has shown promising Phase 2/3 results. The company expects pivotal trial data by mid-2027 and target...
